Influence of allogenic hematopoietic stem cell transplantation on leukemic recurrence after reduced intensity conditioning

Xiao-qing Niu,Quan-yi Lu,Zhao Wang,Jiang-ning Zhao,Peng Zhang

DOI: https://doi.org/10.3321/j.issn:1673-8225.2008.08.016

2008-01-01

Abstract:Aim: Reduced intensity conditioning allogenic hematopoietic stem cell transplantation (RIC-HSCT), the pre-conditional regimen of which is less intensive compared to myeloablative allogenic stem cell transplantation, but greater compared to truly non-myeloablative allogenic stem cell transplantation, is expected to overcome regimen-related toxicity and reduce relapse of leukemia. This study was designed to evaluate recorrence of leukemia and to ientify factors related to relapse after RIC-HSCT. Methods: 1 Twenty-three patients with acute myeloblastic leukemia (AML, n=6), acute lymphoblastic leukemia (ALL, n=7) or chronic myeloblastic leukemia (CML, n=10) were selected from the Department of Hematology in Zhongshan Hospital of Xiamen University from March 2003 to June 2005. There were 10 HLA-identical sibling donors, 12 family partially mismatched donors and 1 unrelated donor. They all signed the informed consent, and the Hospital Ethics Committee permitted the experiment. 2 The RIC regimen including busulfan 4 mg/(kg · d), 2-3 days and cyclophosphamide 50 mg/(kg · d), 2 days were used in all the patients, and fludarabine 30 mg/(m2·d), 3-5 days was added in 19 patients and Ara-c 1-2 g/m2 · d, 1-3 days in 10 patients. Rabbit anti-T-lymphocyte globulin 3.0-5.0 mg/(kg · d), 3-5 days was used in the HLA-mismatched patients. Peripheral stem cells of donors were mobilized before transplantation, and harvested at days 4 and 5. The median of CD34+ cells infused was 4.02 × 106/kg in all patients. Cyclosporine, methotrexate and mycophenolate mofetil were used for the prophylaxis of graft-versus-host disease (GVHD). 3 Short tandem repeat polymerase chain reaction (STR-PCR) was used to detect evidence of donor cell engraftment. Results: 1 All 23 patients achieved successful hemopoiesis reconstitution. No patient died of side effects related to the pre-conditional regimen. After RIC, the lowest counts of peripheral white cells and platelets were (0.01-0.03) × 109 L-1 and (5-20) × 109 L-1, respectively. The duration for granulocytes to exceed 0.5 × 109 L-1 was 11 days and platelets to exceed 30 × 109 L-1 was 12 days. In 22 patients, STR-PCR confirmed that the donor cell was fully implanted 30 days after RIC-HSCT, and the bone marrow showed complete remission. One case was not tested by STR-PCR because of leukemia relapse. 2 Acute GVHD occurred in 9 patients (39.1%) and 19 patients (82.6%) developed chronic GVHD.3All 23 patients were followed up until June 30th 2007. Five patients (21.7%) got recurrence, of which two patients with AML and one patient with CML were recurrent before transplantation and other two were patients with ALL. The recurrence rate was 10% in the patients who were in complete remission before the transplantation. The recurrence time was from 1 to 24 months after the transplantation. Conclusion: 1 In the patients with AML and CML in complete remission before the transplantation, the recurrence rate after RIC-HSCT is not higher than that in myeloablative allogenic stem cell transplantation, and is accompanied by a lower mortality related pre-conditioning regimen. 2 Type of disease, the disease status at the time of transplantation, intensity of pre-conditional regimen and GVHD are important factors for recurrence of leukemia after RIC-HSCT.